Olanzapine is under clinical development by MedinCell and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Olanzapine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olanzapine overview

olanzapine (MDC-TJK) is under development for the treatment of schizophrenia. It is administered by subcutaneous route. It is developed as long-acting PEGylated formulation based on BEPO technology. BEPO consists of copolymers and a biocompatible solvent, where the active pharmaceutical ingredients are suspended.

MedinCell overview

MedinCell is a developer of therapeutic solutions for the healthcare market. It develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. The company’s BEPO provides a controlled release of therapeutic molecules and can be used to improve the treatment of a variety of chronic diseases or short-term illnesses. MedinCell offers peptides and proteins delivery services. MedinCell offers products for various indications including schizophrenia, pain and inflammation, depression, anaesthesia, organ transplant, and others. The company works for profit and non-profit projects and collaborates with partners including pharma, physicians, biotech firms, academics, and foundations. MedinCell is headquartered in Jacou, France.

For a complete picture of Olanzapine’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.